HENLIUS: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 2 CLINICALSTUDY OF HLX43 FOR INJECTION (ANTIBODY-DRUG CONJUGATETARGETING PD-L1 WITH NOVEL DNA TOPOISOMERASE I INHIBITOR)FOR THE TREATMENT OF RECURRENT/METASTATIC ESOPHAGEALSQUAMOUS CELL C
HENLIUS: VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF INNOVATIVE SMALL MOLECULAR HLX99 WAS APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA)
HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - LICENSE AGREEMENT WITH DR. REDDY'S FORHLX15 (RECOMBINANT ANTI-CD38 HUMAN MONOCLONALANTIBODY INJECTION)
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - EUROPEAN COMMISSION (EC) APPROVED SERPLULIMAB INJECTION(TRADE NAME IN MAINLAND CHINA: HANSIZHUANG; EU TRADENAME: HETRONIFLY) IN COMBINATION WITH CHEMOTHERAPYFOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITHEXTENSIVE-STAG
HENLIUS: VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION (BLA) FORPERTUZUMAB BIOSIMILAR HLX11(RECOMBINANT ANTI-HER2 DOMAIN II HUMANIZEDMONOCLONAL ANTIBODY INJECTION) HAS BEEN ACCEPTEDBY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA)
HENLIUS: CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
HENLIUS: JOINT ANNOUNCEMENT - (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING AND THE H SHAREHOLDERS' CLASS MEETING RELATING TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS AND (2) TERMINATION OF THE ME
HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE 1B/2 CLINICAL TRIAL OF HLX43FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETINGPD-L1 WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) INCOMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION)FOR THE TREATMENT OF PATIENTS W
HENLIUS: UPDATE ON QUALIFICATION OF THE JOINT COMPANY SECRETARY
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code
HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code